Research Article

Effects of Different Nonsteroidal Anti-Inflammatory Drugs Combined with Platelet-Rich Plasma on Inflammatory Factor Levels in Patients with Osteoarthritis

Wenxiao Jiang,1 Yijun Zhang,1 Ye Huang,2 and Yunfeng Cheng3

1Department of Sports Medicine, Qilu Hospital of Shandong University, Qingdao 266035, Shandong, China
2Department of Surgery of Traditional Chinese Medicine, The People’s Hospital of South District of Qingdao, Qingdao 266000, Shandong, China
3Department of Orthopedic Surgery, Haiyang Chinese Medicine Hospital, Yantai 265100, Shandong, China

Correspondence should be addressed to Wenxiao Jiang; jiangwenxiao@sdqiluhospital.cn

Received 25 February 2022; Revised 15 March 2022; Accepted 16 March 2022; Published 31 March 2022

Objective. To investigate the effects of different nonsteroidal anti-inflammatory drugs combined with platelet-rich plasma on inflammatory factor levels in patients with osteoarthritis.

Methods. The clinic data of 120 patients with osteoarthritis who were treated in our hospital (June 2019-June 2021) were retrospectively reviewed. All the patients were given platelet-rich plasma. According to the different nonsteroidal anti-inflammatory drugs the patients received, they were equalized into diclofenac sodium group, celecoxib group, and iguratimod group, with 40 cases in each group. After treatment, the patients’ clinical efficacy was compared and analyzed.

Results. After treatment, the pain degrees of the patients in the three groups were gradually reduced. After 4 weeks and 8 weeks of treatment, the statistical differences in the scores of Visual Analogue Scale (VAS) were found among the three groups. Specifically, compared with the other two groups, the iguratimod group had remarkably lower VAS scores ($P < 0.05$) and the celecoxib group had significantly lower VAS scores compared with the diclofenac sodium group ($P < 0.05$). After treatment, the inflammatory factor levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) in the diclofenac sodium group were observably higher compared with the celecoxib group ($P < 0.05$), and the inflammatory factor levels in the celecoxib group were remarkably higher compared with the iguratimod group ($P < 0.05$). Before treatment, no notable difference in the Lysholm scores was found among the three groups, and the patients’ knee joint function was gradually improved after treatment. To be specific, after 4 and 8 weeks of treatment, the iguratimod group had observably higher Lysholm scores compared with the other two groups ($P < 0.05$), and the celecoxib group had significantly higher Lysholm scores compared with the diclofenac sodium group ($P < 0.05$). The iguratimod group got markedly lower Western Ontario and McMaster Universities (WOMAC) score compared with the celecoxib group ($P < 0.05$); Compared with the diclofenac sodium group, the celecoxib group got remarkably lower WOMAC score ($P < 0.05$). During treatment, few patients suffered from mild gastrointestinal discomfort and hepatic dysfunction in the three groups, and no other severe adverse reactions were found. No statistical difference in the total incidence of adverse reactions among the three groups was observed ($P > 0.05$).

Conclusion. The combination of nonsteroidal anti-inflammatory drugs with platelet-rich plasma can further reduce the inflammatory reactions of the patients with osteoarthritis and improve their knee joint function. Significantly, the iguratimod, with high safety, has observably better effects on inhibiting inflammatory factors and improving knee joint function compared with diclofenac sodium and celecoxib.

1. Introduction

Osteoarthritis, as a chronic disease, mainly damages the articular cartilage, with pain, stiffness, and limited movement as the main clinical symptoms. The principle of treating osteoarthritis in clinic is providing graded and individualized treatment according to the patients’ conditions. Especially for the patients in early or medium stage,
the stage treatment measures should be improved as much as possible, which is the current research hotspot in this field. Platelet-rich plasma is the platelet concentration made by the isolated autologous whole blood, and includes a great deal of growth factors and proteins. Platelet-rich plasma can repair damaged cartilage and promote bone healing and has been widely used in orthopedics in recent years. Many previous clinical trials have shown that injecting the platelet-rich plasma into the articular cavity can relieve clinical symptoms of patients with mild and moderate osteoarthritis with effect and can significantly inhibit the expression of inflammatory factors and the degradation of cartilage matrix [1–4]. In the clinical treatment of osteoarthritis, the platelet-rich plasma is frequently adopted in combination with other methods. In addition, when the basic treatment for osteoarthritis is ineffective, the nonsteroidal anti-inflammatory drugs (NSAIDs) are the first choice in further treatment. Besides, they are also the most commonly used drugs to relieve pain and improve joint function in patients with osteoarthritis. The combination of NSAIDs and platelet-rich plasma can guarantee the clinical efficacy of the patients with osteoarthritis. However, it has been found that different NSAIDs can cause different degrees of rash, renal impairment, gastrointestinal complications, and cardiovascular and cerebrovascular risks in the clinical course of medication [5–8]. Based on previous studies, this paper further investigates the effects of different NSAIDs (diclofenac sodium, celecoxib, and iguratimod) combined with platelet-rich plasma on inflammatory factor levels in patients with osteoarthritis.

2. Materials and Methods

2.1. Patients Screening. Inclusion criteria were as follows: ① The patients matched the diagnostic standards for osteoarthritis in Guideline for Clinical Diagnosis and Treatment of Osteoarthritis (2021) [9], and their diagnoses were confirmed by imaging examinations; ② the patients 50 years old or older; ③ the patients’ synovial fluid was yellow, with positive coagulation test, and the leucocyte count in synovial fluid was lower than 2 × 106/L; ④ the patients’ clinical data were complete; and ⑤ the patients and their families were informed of the study and had signed the informed consent. Exclusion criteria were as follows: ① the patients suffered from severe joint deformity; ② the patients were complicated with immune dysfunction, coagulation disorders, organic diseases, or malignant tumors; ③ the patients had bacterial arthritis, gouty arthritis, rheumatoid arthritis, or other joint diseases; ④ the patients had the illness history of ligament rupture or meniscus injury; ⑤ the patients had received surgery on the knees; ⑥ the patients had cognition disorders, language dysfunction or audio-visual disorders; and ⑦ the patients’ conditions were extremely unstable. In the light of the above criteria, 120 patients with osteoarthritis who were treated in our hospital (June 2019–June 2021) were chosen as the study objects.

2.2. Grouping. According to the different nonsteroidal anti-inflammatory drugs the patients received, they were equalized into diclofenac sodium group, celecoxib group, and iguratimod group, and each group had 40 patients. The Hospital Ethics Committee approved this study and was conducted under supervision of this Committee.

2.3. Methods. After the acute stage treatment, the patients in the three groups received different nonsteroidal anti-inflammatory drugs. Patients from the diclofenac sodium group orally took diclofenac sodium sustained release tablets (Specification: 0.1 g; Manufacturer: Sinopharm Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd; NMPA Approval No. H10970209), once a day and 1 tablet once. The patients in the celecoxib group orally took celecoxib capsules (Specification: 0.2 g; Manufacturer: Pfizer Pharmaceuticals LLC; NMPA Approval No. J20120063), once a day and 1 tablet once. The patients in the iguratimod group orally took iguratimod tablets (Specification: 25 mg; Manufacturer: Sincere Pharmaceutical Group Limited; NMPA Approval No. H20110084) after meals in the morning and evening, twice a day and 1 tablet once.

Platelet-rich plasma: all the patients received the treatment of platelet-rich plasma. Forty milliliters of the blood from antecubital vein was collected and the platelet-rich plasma was made by the two-step centrifugation method. The blood was centrifuged at 1450 r/min for 10 minutes for first time. Then, all the clear supernatant and the solid between the solid-liquid interface and 3 mm below the interface were collected and centrifuged at 3370 r/min for 10 minutes. After that, 3/4 of the clear supernatant was removed and the rest was the platelet-rich plasma [10, 11]. Four milliliters of the platelet-rich plasma was injected into the joint lesion sites, and 1 ml of calcium chloride was added to the plasma before injection to activate the platelets. The patients received such treatment once a week, and one course of treatment lasted for three weeks. The patients received two courses, with 1-week interval between the two courses.

2.4. Observed Indexes. The patients’ age, course of disease, body mass index (BMI), sex, focus of infection, K-L classification, educational level, and other general data were collected. Besides, 5 ml of fasting venous blood was drawn and collected, with serum being separated from the blood sample. Then, the patients’ inflammatory factor levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) was determined by enzyme-linked immunosorbent assay. Their high-sensitivity C-reactive protein (hs-CRP) levels were determined by immunoturbidimetry.

Severity of pain: the Visual Analogue Scale (VAS), with high sensitivity, was adopted to evaluate the patients’ severity of pain. The patients needed to look at the “pain scale” (a 10-centimeter-long vernier caliper, with 10 scales marked on one side and “0” and “10” at both ends) and to state a number between 0 and 10. Zero signified no pain; 1–3 points signified slight pain which was tolerable; 4–6 points signified the tolerable pain which influenced the patients’ sleep; 7–9 points signified the intolerable pain which became gradually intense and influenced the patients’ sleep and appetite; and 10 points represented the intolerable severe pain.

Reference: [1–4, 5–8]
Knee joint function: the Lysholm knee scoring scale [12] was formulated to assess patients' knee joint function. This scale was formulated by Lysholm and Gillquist in 1982, and its validity and reliability have been confirmed by clinical trials. This scale included 8 items of limp, support, locking, pain, instability, swelling, stair climbing, and squatting, with the total score of 100 points. Higher points indicated better knee joint function.

Osteoarthritis index: The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index was employed to assess the severity of osteoarthritis and clinical efficacy and included three aspects of pain, stiffness and physical function, with 24 items in total. This scale covered the basic symptoms and physical signs of osteoarthritis, and higher scores indicated more severe osteoarthritis. The Cronbach’s α coefficients of every dimension was 0.6–0.83, and factor analysis showed good construct validity.

The patients’ adverse reactions during treatment were recorded and collected.

2.5. Statistical Treatment. In this study, the software SPSS22.0 was adopted to calculate the differences among groups and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used to draw graphs of the data. The study included count data and measurement data. The count data were tested by X² and expressed by (n (%)). The measurement data were tested by t and expressed by (x ± s). When P < 0.05, the differences were considered statistically significant.

3. Results

3.1. General Data. No notable difference in age, course of disease, body mass index (BMI), sex, focus of infection, K-L classification, educational level, and other general data was discovered among the three groups (P > 0.05; Table 1).

Grade I: the joint space was suspected of becoming narrow, and the osteophyte might occur; Grade II: the patients had obvious osteophyte, and the joint space was suspected of becoming narrow.

From the perspective of the severity of knee osteoarthritis, the patients in grade I and grade II accorded with the study object.

3.2. Severity of Pain. The pain degrees of the patients in the three groups were gradually reduced after treatment. After 4 weeks and 8 weeks of treatment, the statistical differences in the VAS scores were found among the three groups. Specifically, the iguratimod group had remarkably lower VAS scores compared with the other two groups (P < 0.05), and the celecoxib group had significantly lower VAS scores compared with the diclofenac sodium group (P < 0.05; Figure 1).

3.3. Inflammatory Factor Levels. According to the statistical data in Table 2, IL-6, TNF-α, and hs-CRP in the diclofenac sodium group were observably higher compared with the celecoxib group after treatment (P < 0.05). The celecoxib group achieved remarkably higher inflammatory factor levels compared with the iguratimod group after treatment (P < 0.05).

3.4. Knee Joint Function. Before treatment, no notable difference in the Lysholm scores was found among the three groups, and the patients’ knee joint function was gradually improved after treatment. To be specific, after 4 weeks and 8 weeks of treatment, the iguratimod group had observably higher Lysholm scores compared with the other two groups (P < 0.05), and the celecoxib group had signally higher Lysholm scores compared with the diclofenac sodium group (P < 0.05; Table 3).

3.5. Osteoarthritis Indexes. The iguratimod group got markedly lower WOMAC score compared with the celecoxib group (P < 0.05). Compared with the diclofenac sodium group, the celecoxib group got remarkably lower WOMAC score (P < 0.05; Figure 2).

3.6. Adverse Reactions. During treatment, there were few cases suffering from mild gastrointestinal discomfort and hepatic dysfunction in the three groups, and no other severe adverse reactions were found. No statistical difference in the total incidence of adverse reactions among the three groups was discovered (P > 0.05).

4. Discussion

Osteoarthritis is a progressive joint disease induced by the imbalance of intra-articular stress function and characterized by the repair disorders of articular cartilages. The main physiological changes are progressive destruction of the affected articular cartilage and imbalance between the articular cartilage’s decomposition and anabolism, and the synthesis and decomposition caused by dysregulation of various cytokines play an important role in joint degeneration [13]. Therefore, how to repair damaged cartilage and prevent further damage is the key to treating osteoarthritis. At the same time, understanding the damage mechanism of articular cartilage tissue is a prerequisite for the treatment of osteoarthritis. According to modern basic medical research, polypeptide growth factors can regulate the synthetic and catabolic processes of cartilage [14]. Under normal circumstances, the balance between synthesis and decomposition of articular cartilage matrix is maintained by the dynamic balance in quantity between the synthetic and catabolic cytokines in the body. IL-6 and TNF-α are the important catabolic cytokines involved in the pathogenesis of osteoarthritis and are closely related to the degradation of intra-articular cartilage matrix, synovial lesion and reduction of chondrocyte function in patients with osteoarthritis. After the extracellular matrix of articular cartilage is decomposed by a variety of MMPs, the articular cartilage expands. As a result, the resistance of articular cartilage to the outside world is reduced, causing further damage to the articular cartilage. Generally, there is little differences in the
Table 1: Comparison of general data (n = 40).

| Observed indexes | Diclofenac sodium group | Celecoxib group | Iguratimod group | P     |
|------------------|-------------------------|-----------------|------------------|-------|
| Age (years)      | 62.45 ± 3.57            | 62.78 ± 3.40    | 62.31 ± 3.62     | <0.005|
| Course of disease (years) | 1.85 ± 0.46            | 1.88 ± 0.44     | 1.89 ± 0.50      | <0.005|
| BMI (kg/m²)      | 23.71 ± 2.28            | 23.84 ± 2.30    | 23.69 ± 2.32     | <0.005|
| Sex              |                         |                 |                  | <0.005|
| Male             | 27 (67.5)               | 24 (60)         | 26 (65)          |       |
| Female           | 13 (32.5)               | 16 (40)         | 14 (35)          |       |
| Focus of infection |                       |                 |                  | <0.005|
| Single knee      | 31 (77.5)               | 28 (70)         | 30 (75)          |       |
| Both knees       | 9 (22.5)                | 12 (30)         | 10 (25)          |       |
| K-L classification |                     |                 |                  | <0.005|
| Grade I          | 14 (35)                 | 15 (37.5)       | 13 (32.5)        |       |
| Grade II         | 26 (65)                 | 25 (62.5)       | 27 (67.5)        |       |
| Educational level |                       |                 |                  | <0.005|
| Under junior middle school | 22 (55)               | 24 (60)         | 25 (62.5)        |       |
| Junior middle school and above | 18 (45)               | 16 (40)         | 15 (37.5)        |       |

K-L classification represented the classification of the severity of knee osteoarthritis according to Kellgren–Lawrence grading system.

Figure 1: Comparison of VAS scores. The abscissa indicated before treatment, after 4 weeks of treatment, and after 8 weeks of treatment, and the ordinate indicated the VAS score (points). The VAS scores in the diclofenac sodium group before treatment, after 4 weeks of treatment, and after 8 weeks of treatment were (6.33 ± 1.42), (5.64 ± 1.06), and (4.01 ± 0.58) points, respectively. The VAS scores in the celecoxib group before treatment, after 4 weeks of treatment, and after 8 weeks of treatment were (6.35 ± 1.35), (4.59 ± 1.02), and (3.50 ± 0.82) points, respectively. The VAS scores in the iguratimod group before treatment, after 4 weeks of treatment, and after 8 weeks of treatment were (6.28 ± 1.41), (3.22 ± 0.97), and (2.35 ± 0.70) points, respectively. *The remarkable differences in VAS scores between the diclofenac sodium group and the celecoxib group after 4 weeks and 8 weeks of treatment from left to right (t = 4.430 and 3.211, P < 0.05); **the remarkable differences in VAS scores between the diclofenac sodium group and the iguratimod group after 4 weeks and 8 weeks of treatment from left to right (t = 10.652 and 11.549, P < 0.05); and ***the remarkable differences in VAS scores between the celecoxib group and the iguratimod group after 4 weeks and 8 weeks of treatment from left to right (t = 6.156 and 6.746, P < 0.05).

Table 2: Comparison of inflammatory factor levels.

| Group             | IL-6 (ng/mg) | TNF-α (pg/mg) | Hs-CRP (mg/L) |
|-------------------|--------------|---------------|---------------|
| Diclofenac sodium group | 24.68 ± 4.80 | 55.18 ± 3.26  | 3.45 ± 1.20   |
| Celecoxib group   | 15.22 ± 3.16 * | 36.71 ± 4.12 * | 3.06 ± 1.04 * |
| Iguratimod group  | 10.35 ± 2.47 ** | 25.61 ± 3.23 ** | 2.08 ± 0.95 ** |

*Statistically significant difference compared with the diclofenac sodium group (P < 0.05); *statistically significant difference compared with the celecoxib group (P < 0.05).
amount between synthetic cytokines and catabolic cytokines in the early stage of osteoarthritis. The disease progression caused by untimely treatment leads to the degeneration of more articular chondrocytes, and the production of plentiful catabolic cytokines, like the overexpression of IL-6, TNF-α, hs-CRP, and so on. As a result, the chondrocytes are inhibited from dividing and the proteoglycan is inhibited from synthesizing. With the pathological increase of catabolic cytokines, like the overexpression of IL-6, TNF-α, and hs-CRP, the inflammatory factors of IL-6, TNF-α, and hs-CRP trigger immune response and aggravate cartilage injury.

Platelet-rich plasma, the plasma whose platelet concentration is 2–7 times the concentration of the whole blood, has been widely employed in bone and joint diseases at present. Meanwhile, the treatment of osteoarthritis is also one of the important research directions. In the treatment of osteoarthritis, platelet-rich plasma has the advantages of minimal invasion, economy, less complications, and less pain compared with surgical treatment [15, 16]. Platelet-rich plasma, rich in various growth factors and cytokines, plays a crucial part in the normal expression of cartilage cells and is an important treatment measure to regulate the dynamic balance between synthetic cytokines and catabolic cytokines. In addition, NSAIDs are also commonly used in the early treatment of osteoarthritis, and their mechanisms of action are as follows: (1) NSAIDs reduce the synthesis of prostaglandin by inhibiting cyclooxygenase activity; (2) NSAIDs can reduce the stimulation to nerve endings by inhibiting lymphocyte activity and differentiation of activated T lymphocytes; and (3) NSAIDs act directly on polymodal nociceptors to block the formation and release of pain-producing substances [17–20]. Cyclooxygenase includes two isozymes—cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1, a kind of constitutive enzyme, mostly exists in gastrointestinal tract and kidney and can promote the synthesis of physiological prostaglandins and regulate the physiological activities of normal tissue cells. COX-2, an inducible type enzyme, is generated under the induction of injury or inflammatory factors and catalyzes the synthesis of prostaglandins, triggering a series of inflammatory responses and pain. According to previous studies, while relieving the patients’ postoperative pain, NSAIDs could also inhibit the release of bradykinin and exert anti-inflammatory effect by controlling the platelet concentration [21–24].

In this study, all the patients received different NSAIDs (diclofenac sodium, celecoxib, and iguratimod) combined with platelet-rich plasma and the patients’ clinic data were retrospectively reviewed. The treatment results were as follows. The pain degrees of the patients in the three groups were gradually reduced after treatment. After 4 weeks and 8 weeks of treatment, the statistical differences in the VAS scores were found among the three groups. Specifically, compared with the other two groups, the iguratimod group had remarkably lower VAS scores (P < 0.05); compared with the diclofenac sodium group, the celecoxib group had significantly lower VAS scores (P < 0.05). These results were in line with the research report of PU CHUNXUE et al. [25], confirming that all the NSAIDs had good analgesic effects and iguratimod had a better analgesic effect compared with the other two drugs. After treatment, the inflammatory factor levels of IL-6, TNF-α, and hs-CRP in the diclofenac sodium group were observably higher compared with the celecoxib group (P < 0.05), and the inflammatory factor levels in the celecoxib group were remarkably higher compared with the iguratimod group (P < 0.05). Before treatment, no notable difference in the Lysholm scores was discovered among the three groups, and the patients’ knee

### Table 3: Comparison of Lysholm scores.

| Group               | n  | Before treatment | After 4 weeks of treatment | After 8 weeks of treatment |
|---------------------|----|------------------|---------------------------|---------------------------|
| Diclofenac sodium   | 40 | 62.53 ± 4.51     | 67.85 ± 3.87              | 70.83 ± 2.56              |
| Celecoxib           | 40 | 63.14 ± 3.86*    | 75.29 ± 4.01*             | 79.69 ± 3.17*             |
| Iguratimod          | 40 | 62.82 ± 4.49**   | 81.06 ± 3.25**            | 88.46 ± 3.75**            |

*Statistically significant difference compared with the diclofenac sodium group (P < 0.05); **statistically significant difference compared with the celecoxib group (P < 0.05).

Figure 2: Comparison of WOMAC scores. The abscissa indicated before treatment and after treatment, and the ordinate indicated the WOMAC score (points). The WOMAC scores in the diclofenac sodium group before treatment and after treatment were (49.16 ± 5.21) and (44.51 ± 4.20) points, respectively. The WOMAC scores in the celecoxib group before treatment and after treatment were (48.79 ± 5.28) and (35.47 ± 3.60) points, respectively. The WOMAC scores in the iguratimod group before treatment and after treatment were (48.85 ± 5.25) and (23.54 ± 4.31) points, respectively. The remarkable difference in the WOMAC scores between the diclofenac sodium group and the celecoxib group and between the diclofenac sodium group and the iguratimod group from top to bottom (t = 10.336 and 20.038, P < 0.001); **the remarkable difference in the WOMAC scores between the celecoxib group and the iguratimod group (t = 13.436, P < 0.001).
joint function was gradually improved after treatment. To be specific, after 4 and 8 weeks of treatment, the iguratimod group had observably higher Lysholm scores compared with the other two groups \((P < 0.05)\), and the celecoxib group had signally higher Lysholm scores compared with the diclofenac sodium group \((P < 0.05)\). The iguratimod group got markedly lower WOMAC score compared with the celecoxib group \((P < 0.05)\). Compared with the diclofenac sodium group, the celecoxib group got remarkably lower WOMAC score \((P < 0.05)\). According to these results, iguratimod had better anti-inflammatory effect and better improvement of knee joint function in patients with osteoarthritis compared with celecoxib and diclofenac sodium, and the efficacy of celecoxib was better than that of diclofenac sodium. Diclofenac sodium, as a kind of nonspecific NSAIDs, inhibits the inflammatory response and relieves pain by promoting the synthesis of proteoglycans in the cartilage matrix. Diclofenac sodium exerts the inhibition of both COX-1 and COX-2. Celecoxib, as a kind of specific NSAIDs, only inhibits COX-2. Igratimod, a kind of new NSAIDs, can exert anti-inflammatory effects by inhibiting the bradykinin in inflammatory response and inhibit the immunoglobulins of B cells from generating. Igratimod can also control rheumatoid arthritis (RA) and bone loss caused by RA by inhibiting IL-1β, TNF-α, IL-6, IL-8, MPC-1, and other cytokines from synthesizing, so as to prevent bone absorption and promote bone formation. During treatment, there were few cases suffering from mild gastrointestinal discomfort and hepatic dysfunction in the three groups, and no other severe adverse reactions were found. No statistical difference in the total incidence of adverse reactions among the three groups was discovered \((P > 0.05)\), which might be caused by the small sample size, and the sample size should be enlarged in the follow-up studies.

In conclusion, the combination of NSAIDs with platelet-rich plasma can further reduce the inflammatory reactions of the patients with osteoarthritis and improve their knee joint function. Significantly, iguratimod, with high safety, has observably better effects on inhibiting inflammatory factors and improving knee joint function compared with diclofenac sodium and celecoxib. Therefore, the iguratimod is the first choice in clinic and can be used in combination with the other two drugs according to the patients’ conditions, but its dosage should be paid attention to.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

[1] K. Petersen, A. E. Olesen, O. Simonsen, and L. Arendt-Nielsen, “Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis,” *Pain*, vol. 160, no. 2, pp. 486–492, 2019.

[2] Y. Garg, J. Singh, and H. S. Sohal, “Comparison of clinical effectiveness and safety of newer nonsteroidal anti-inflammatory drugs in patients of osteoarthritis of knee joint: a randomized, prospective, open-label parallel-group study,” *Indian Journal of Pharmacology*, vol. 49, no. 5, pp. 383–389, 2017.

[3] J. N. Katz, S. R. Smith, J. E. Collins et al., “Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities,” *Osteoarthritis and Cartilage*, vol. 24, no. 3, pp. 409–418, 2016.

[4] D. J. Hunter, S. Radominski, S. R. Ulloa et al., “Observed efficacy of subcutaneous tanezumab or oral nonsteroidal anti-inflammatory drugs in patients with osteoarthritis: subgroup analyses of a phase 3 study,” *Osteoarthritis and Cartilage*, vol. 29, no. Suppl.1, pp. S85–S86, 2021.

[5] G. Honvo, V. Leclercq, and A. Geerinck, “Adverse events associated with topical nonsteroidal anti-inflammatory drugs (nsaids) in osteoarthritis: a systematic review and meta-analysis of randomised, placebo-controlled trials,” *Osteoporosis International: A Journal Established As Result of Cooperation Between The European Foundation for Osteoporosis and the National Osteoporosis Foundation of The USA*, vol. 29, no. Suppl.1, p. S562, 2018.

[6] D. J. Hunter, S. Radominski, S. Rodriguez Ulloa et al., “Joint safety and neurologic events with subcutaneous tanezumab or oral nonsteroidal anti-inflammatory drugs in subgroups of patients with osteoarthritis from an 80-week phase 3 study,” *Osteoarthritis and Cartilage*, vol. 29, no. Suppl.1, pp. S246–S247, 2021.

[7] D. Yvonne, M. Patrick, and Y. Tony, “Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies,” *Postgraduate Medicine*, vol. 133, no. 8, pp. 879–894, 2021.

[8] G. Yashika, S. Satinder, and H. Sohal, “Comparison of clinical effectiveness and safety of newer nonsteroidal anti-inflammatory drugs in patients of osteoarthritis of knee joint: a randomized, prospective, open-label parallel-group study,” *Indian Journal of Pharmacology*, vol. 49, no. 5, pp. 383–389, 2017.

[9] T. Katsumo, K. Togo, N. Ebata et al., “Burden of renal events associated with nonsteroidal anti-inflammatory drugs in patients with osteoarthritis and chronic low back pain: a retrospective database study,” *Pain and Therapy*, vol. 10, no. 1, pp. 443–455, 2021.

[10] D. G. Wolff, C. Christophersen, S. M. Brown, and M. K. Mulcahey, “Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis,” *The Physician and Sportsmedicine*, vol. 49, no. 4, pp. 381–391, 2021.

[11] K. Bennell, D. Hunter, and K. Paterson, “Platelet-rich plasma for the management of hip and knee osteoarthritis,” *Current Rheumatology Reports*, vol. 19, no. 5/6, 2017.

[12] Y.-T. Wu, K.-C. Hsu, T.-Y. Li, C.-K. Chang, and L.-C. Chen, “Effects of platelet-rich plasma on pain and muscle strength in patients with knee osteoarthritis,” *American Journal of Physical Medicine & Rehabilitation*, vol. 97, no. 4, pp. 248–254, 2018.

[13] Y. Han, H. Huang, J. Pan et al., “Meta-analysis comparing platelet-rich plasma vs hyaluronic acid injection in patients with knee osteoarthritis,” *Pain Medicine*, vol. 20, no. 7, pp. 1418–1429, 2019.
[14] M. V. Sowmya and M. Mangayarkarasi, “Effect of physiotherapy intervention after platelet rich plasma procedure in subjects with grade 3 osteoarthritis knee,” Research Journal of Pharmacy and Technology, vol. 13, no. 5, pp. 2065–2068, 2020.

[15] H. Rashid and C. K. Kwoh, “Should platelet-rich plasma or stem cell therapy Be used to treat osteoarthritis?” Rheumatic Disease Clinics of North America, vol. 45, no. 3, pp. 417–438, 2019.

[16] Y. C. Chen, Y. M. Hsu, K. P. Tan, H. W. Fang, and C. H. Chang, “Intraarticular Injection for Rabbit Knee Osteoarthritis: Effectiveness Among Hyaluronic Acid, Platelet-Rich Plasma, and Mesenchymal Stem cells,” Journal of the Taiwan Institute of Chemical Engineers, vol. 91, Article ID 91138, 2018.

[17] T. Vinicius, D. Saeid, T. Chris, and L. B. Tony, “Oral versus topical diclofenac sodium in the treatment of osteoarthritis,” Journal of Pain & Palliative Care Pharmacotherapy, vol. 31, no. 2, pp. 113–120, 2017.

[18] V. Povoroznyuk, N. Grygorieva, M. Bystrytska, T. Kottun, and A. Pidlisetskiy, “Comparative study of amtolmetin guacil and diclofenac sodium in patients with knee osteoarthritis,” Osteoarthritis and Cartilage, vol. 25, no. Suppl.1, p. S421, 2017.

[19] J. A. Wale and A. O. Luqman, “Effects of single or combined administration of salmon calcitonin and omega-3 fatty acids vs. diclofenac sodium in sodium monoiodoacetate-induced knee osteoarthritis in male Wistar rats,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 28, no. 6, pp. 573–582, 2017.

[20] B. Crivelli, E. Bari, and S. Perteghella, “Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis,” European Journal of Pharmaceutics and Biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V, vol. 137, Article ID 13737, 2019.

[21] S. M. Smith, R. M. Cooper-Dehoff, and M. Rhonda, “Fixed-dose combination amlodipine/celecoxib (consensi) for hypertension and osteoarthritis,” The American Journal of Medicine, vol. 132, no. 2, pp. 172–174, 2019.

[22] E. Losina, I. M. Usiskin, S. R. Smith et al., “Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation,” Osteoarthritis and Cartilage, vol. 26, no. 5, pp. 641–650, 2018.

[23] S. L. Navarro, M. Herrero, H. Martinez et al., “Differences in serum biomarkers between combined glucosamine and chondroitin versus celecoxib in a randomized, double-blind trial in osteoarthritis patients,” Anti-Inflammatory & Anti-allergy Agents in Medicinal Chemistry, vol. 19, no. 2, pp. 190–201, 2020.

[24] A. Lubis, W. Wang, G. Lima, R. Fayyad, and C. Walker, “Comparing the safety and efficacy of celecoxib for the treatment of osteoarthritis in asian and non-asian populations: an analysis of data from two randomized, double-blind, placebo-controlled, active-comparator trials,” Pain and Therapy, vol. 6, no. 2, pp. 235–242, 2017.

[25] C. Pu, X. Jiang, Y. Sun, H. Lin, and S. Li, “Efficacy and safety between early use and late use of celecoxib in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study,” Inflammopharmacology, vol. 29, no. 6, pp. 1761–1768, 2021.